a Objective: To identify and characterize cytotoxic T-cell (CTL) epitopes for HIV-1 clade E using eight known HLA-A Ã 1101-restricted HIV-1 clade B epitopes.
Introduction
There is growing evidence that HIV-1-speci®c cytotoxic T lymphocytes (CTL) inhibit HIV-1 replication in HIV-1-infected individuals [1±5] and prevent HIV-1 infection [6, 7] . Recent studies of SIV demonstrated an inverse relationship between SIV-speci®c CTL activity and disease onset [8±11] . These ®ndings strongly suggest that a vaccine which elicits HIV-1-speci®c CTL would prevent HIV-1 infection and delay progression to AIDS.
Geographically distinct epidemics of HIV-1 subtypes have been identi®ed. In North America and Europe, most HIV-1-seropositive individuals are infected with clade B virus, while in Africa and Asia, two largest epicentres of global HIV/AIDS epidemic, most HIV-1-seropositive individuals are infected with non-clade B virus [12±14] . In Asian countries, HIV-1 clade E and clade C infection were observed in the majority of HIV-1-seropositive individuals [14] . The former is the most prevalent strain in South-East Asia while the latter is spreading rapidly in India. Both HIV-1 clade C and clade E infections are observed in south China [15, 16] . In Japan, haemophilia patients are infected with HIV-1 clade B while clade E infection is increasing through heterosexual transmission.
Most HIV-1-speci®c CTL epitopes have been de®ned for clade B [17] . Several studies provided CTL epitopes for HIV-1 clades A [18, 19] and C [18] , but there are no reported CTL epitopes for HIV-1 clade E. Identi®-cation of CTL epitopes for HIV-1 clades E and C is critical for investigating the role of CTL in individuals infected with these HIV-1 clades and for designing HIV-1 vaccines for trial in Asia.
In the present study, we focused on HLA-A Ã 1101-restricted epitopes because HLA-A Ã 1101 is a common allele in East and South-East Asia, and is the most frequent allele in Thailand [20] . We previously identi®ed four HLA-A Ã 1101-restricted CTL epitopes for HIV-1 clade B by reverse immunogenetics, and four others have been reported by other investigators [21, 22] . We used these HIV-1 clade B epitopes to identify CTL epitopes for HIV-1 clade E. Cross-clade and clade-speci®c CTL recognition for these epitopes was analysed using CTL clones and bulk CTL cultures established from Thai individuals infected with HIV-1 clade E and Japanese individuals infected with HIV-1 clade B. Furthermore, to investigate the antigenicity of these epitopes in HIV-1-infected CD4 T cells, CTL recognition for the identi®ed clade E-speci®c and cross-clade epitopes was investigated using CD4CX CR4 T cells infected with an HIV-1 clade E clone.
Materials and methods
Cells C1R and RMA-S cells were maintained in RPMI 1640 medium supplemented with 10% foetal calf serum (FCS). C1R cells expressing HLA-A Ã 1101 (C1R-A Ã 1101) and TAP-defective RMA-S cells expressing HLA-A Ã 1101 (RMA-S-A Ã 1101) were previously generated [23] and were maintained in RPMI 1640 medium supplemented with 10% FCS and 0.15 mg/ml hygromycin B. The Epstein±Barr virus-transformed cell line Tm was previously generated from an individual Tm (HLA-A Ã 1101/A Ã 2402, B Ã 5201/B Ã 5201, Cw Ã 0701/Cw Ã 1202) [24] and was maintained in RPMI 1640 medium supplemented with 10% FCS. 721.221-CD4 cells were generated by transfection of the CD4 gene (pBMG hyg CD4) into 721.221 cells that express CXCR4 (data not shown) but lose HLA class I. 721.221-CD4-A Ã 1101 cells were subsequently generated by transfection of the HLA-A Ã 1101 gene into 721.221-CD4 cells.
CTL clones
Pol 424±432-34, Pol 424±432-64, Pol 675±683-133, Pol 894±903-14, Pol 894±903-18 and Env 202±210-56 CTL clones were generated previously [21, 22] .
Synthetic peptides
Peptides were prepared by using an automated multiple peptide synthesizer (Shimadzu Model PSSM-8; Shimadzu Co., Kyoto, Japan) and then examined by mass spectrometry. Peptides with more than 90% purity were used in this study.
Peptide binding assay
Binding of HIV-1-derived peptides to HLA-A Ã 1101 was examined by a peptide stabilization assay as described previously [23] . Brie¯y, RMA-S-A Ã 1101 cells were cultured for 16 h at 268C and then pulsed with peptides (10 ±3 to 10 ±7 M) for 1 h at 268C. After further incubation for 3 h at 378C, peptide-pulsed cells were stained by the anti-HLA class I á 3 domain monoclonal antibody (mAb) TP25.99 [25] and thē uoresceine isothiocyanate-conjugated IgG fraction of sheep anti-mouse Ig (Silenius Laboratories, Hawthorn Victoria, Australia). The mean¯uorescence intensity (MFI) was measured using a FACS Calibur (BD Biosciences, San Jose, California, USA). The MFI of RMA-S-A Ã 1101 cells was obtained by subtracting the MFI value of RMA-S-A Ã 1101 cells incubated for 3 h at 378C from that of control cells cultured at 268C. HLA-A Ã 1101-binding peptides were de®ned as those which at a concentration of 10 ±3 M caused . 25% increase in MFI compared to control RMA-S-A Ã 1101 cells cultured at 268C. The peptide concentration that yielded the half-maximal MFI level (the BL 50 value) was calculated.
Patients
Blood samples were collected with informed consent from seven HLA-A Ã 1101 patients (TT-005, TT-007, TT-008, TT-009, TU-002, TU-003 and TU-007) with chronic HIV-1 clade E infection at Siriraj Hospital and ®ve HLA-A Ã 1101 patients (KI-005, KI-015, KI-030, KI-035 and KI-036) with chronic HIV-1 clade B infection at the International Medical Center of Japan. HLA typing was determined by HLA genotyping. All patients included in the present study had HLA-A Ã 1101. Identi®cation of HIV-1-subtype was performed by sequencing the env gene.
Induction of peptide-speci®c CTL in PBMC from HIV-1-infected individuals carrying HLA-A Ã 1101 Speci®c CTL were induced from peripheral blood mononuclear cells (PBMC) of HIV-1-infected Thai and Japanese individuals carrying HLA-A Ã 1101. PBMC (1 3 10 6 ) were stimulated with HLA-A Ã 1101-binding peptide (10 ±6 M) in culture medium [RPMI 1640 medium supplemented with 10% FCS and 200 U/ml recombinant human interleukin (IL)-2]. The culture was maintained for 2 weeks before CTL activity was assayed as described below. As relative speci®c lysis of the bulk cultured T cells for nonspeci®c peptide (HLA-B Ã 3501 binding peptide: DP NPQEVVL) was 2.7 AE 3.0% in HIV-1 clade Binfected individuals and 3.5 AE 3.5% in HIV-1 clade Einfected individuals, more than 10% of relative speci®c lysis was evaluated as positive CTL lysis. 3 /well) were added to effector cells into Ubottom 96-well microtiter plates. The mixtures were incubated for 4 h (targets infected with vT157) or 6 h (targets infected with vT141) at 378C, as the HIV-1 Nef recombinant vaccinia virus-infected target cells are weakly recognized by CTL if the mixtures were incubated for 4 h (data not shown). The activities of bulk T-cell cultures for target cells infected with recombinant vaccinia virus were tested at an effector : target (E : T) ratio of 10 : 1.
Statistical analysis

HIV-1 clade E clone p93JP-NH1
The replication-competent molecular clone of HIV-1 clade E (CRF01_AE), p93JP-NH1, was isolated from a Japanese individual infected with HIV-1 clade E virus. The full-length nucleotide sequence was determined to con®rm that this clone belongs to clade E.
CTL assay for target cells infected with HIV-1 clade E
The virus stock was produced from HeLa cells transfected with p93JP-NH1. 721.221-CD4-A Ã 1101 cells were exposed to the virus for several days. The cells were used as target cells for a CTL assay when infection of . 80% cells was con®rmed by intracellular staining of HIV-1 p24 antigen. Infected cells (1 3 10 5 ) were labelled with 51 Cr as described above. Labelled target cells (5 3 10 3 /well) were added with effector cells into U-bottom 96-well microtiter plates, and the mixtures were incubated for 4 h at 378C. The activities of CTL clones or bulk T-cell cultures for the target cells were tested at the indicated E : T ratios.
Results
Variants of HLA-A Ã 1101-restricted CTL epitopes in HIV-1 clades A-E In addition to four previously reported HLA-A Ã 1101-restricted clade B epitopes (Pol 313±321, Nef 84±92, Gag 83±90 and Gag 349±359) [26±29], we recently identi®ed further four epitopes (Pol 424±432, Pol 675±683, Pol 894±903 and Env 202±210) [21, 22] . We searched reported HIV-1 sequences (HIV sequence database, Los Alamos National Laboratory, Los Alamos, New Mexico, USA) for major variants of these epitopes in HIV-1 clades A±E (Table 1 ). This search revealed that Pol 894±903 (AVFIHNFKRK) and Pol 313±321 (AIFQSSMTK) are highly conserved between clades A±E and that Pol 424±432 (QIYA GIKVK) is conserved between clade B and clade E. The majority of sequences corresponding to the other ®ve epitopes were found to be different between HIV-1 clade B and clade E. These observations imply that Pol 894±903-and Pol 313-321-speci®c CTL are induced in all individuals infected with HIV-1, regardless of the clade, while clade-or clade group-speci®c CTL are induced by the other six epitopes. We focused on CTL recognition of these eight epitopes in HIV-1 clade E-infected individuals to identify clade E epitopes and to investigate cross-clade or clade-speci®c recognition of clade B and E epitopes by CTL between the clades B and E. HIV-1 clade B-infected Japanese individuals(KI-005, KI-015, KI-030, KI-035 and KI-036). CTL activities for these three epitopes were observed in PBMC from both HIV-1 clade B-infected and HIV-1 clade E-infected HLA-A Ã 1101 individuals (Fig. 1) . CTL activities for Pol 313-321 and Pol 424-432 were more frequently observed in clade E-infected individuals compared to clade B-infected individuals.
There are two major variants of Pol 424±432 in HIV-1 clades A±E: Pol 424±432-9R (QIYAGIKVR) is observed in clades B and E, whereas Pol 424±432-4P9R (QIYPGIKVR) is observed predominantly in clades C and D (Table 1) . CTL recognition for these two major variants was investigated using a CTL clone speci®c for Pol 424±432 (Pol 424±432-34). This clone recognized the Pol 424±432-9R peptide but failed to recognize the Pol 424±432-4P9R peptide (Fig. 2a) . This suggests that in addition to Pol 424±432, Pol 424±432-9R is a cross-clade CTL epitope. Recognition for Pol 424±432-9R peptide was about 10 times lower than that for Pol 424±432 peptide (Fig. 2a) . The binding af®nity of the two variant peptides to HLA-A Ã 1101 was almost identical, but about 10 times lower than that of Pol 424±432 (Fig. 2b) . This indicates that reduced recognition of CTL clone Pol 424±432-34 for the Pol 424±432-9R variant is due to reduced af®nity of the peptide to HLA-A Ã 1101, and that the substitu- 
a The ID described for each peptide is consistent with that used in Fig. 1 (Fig. 1) . These results con®rmed that these peptides are HLA-A Ã 1101-restricted CTL epitopes. Clade E-speci®c variants of these epitopes induced speci®c CTL in PBMC from at least two of seven HIV-1 clade E-infected individuals (Fig. 1) .
We generated a CTL clone speci®c for the clade E epitope Pol 675±683-5E from an individual infected with HIV-1 clade E (TT-007). This clone (Pol 675± 683-5E-3) and a previously generated Pol 675±683-speci®c CTL clone (Pol 675±683-133) were used to investigate cross-recognition of clade B-and E-speci®c Pol 675±683 variants. CTL clone Pol 675±683-133 failed to recognize Pol 675±683-5E and Pol 675±683-5K8E variant peptides (Fig. 3a, upper) , whereas CTL clone Pol 675±683-5E-3 showed weak recognition for Pol 675±683 but failed to recognize Pol 675±683-5K8E (Fig. 3a, middle) . The binding af®nity of these peptides to HLA-A Ã 1101 was identical (Fig. 3a, lower) . These results indicate that the difference at P5 between Pol 675±683 and Pol 675±683-5E is critical for TCR recognition by these CTL clones, and similarly that either one or both difference(s) at P5 and P8 between Pol 675±683-5K8E and Pol 675±683 or Pol 675±683-5E affect(s) TCR recognition by these CTL clones.
The Nef 84±92 variant Nef 84±92-2L is also an HIV-1 clade-B-speci®c sequence, while the variant Nef 84± 92-2F6F is found predominantly in clades C and E (Table 1) . Nef 84±92-2L-speci®c bulk CTL generated from an HIV-1 clade B-infected individual recognized Nef 84±92 peptide, but failed to recognize Nef 84± 92-2F6F peptide (Fig. 3b, upper) . Conversely, Nef 84±92-2F6F-speci®c bulk CTL generated from a clade E-infected individual recognized neither Nef 84±92 peptide nor Nef 84±92-2L peptide (Fig. 3b, middle) . The binding af®nity of Nef 84±92-2F6F peptide to HLA-A Ã 1101 was 10±50 times lower than that of Nef 84±92 and Nef 84±92-2L peptides (Fig. 3b, lower) . These results suggest that the substitutions at P2 and P6 are critical for both peptide binding to HLA-A Ã 1101 and TCR recognition by speci®c CTL.
Gag 349±359 is found predominantly in HIV-1 clades A, B, and C whereas Gag 349±359-9S predominates in clades C, D and E (Table 1) . Gag 349±359-speci®c bulk CTL generated from an HIV-1 clade B-infected individual failed to recognize the Gag 349±359-9S variant peptide (Fig. 3c, upper) . Similarly, Gag 349± 359-9S-speci®c bulk CTL generated from an HIV-1 clade E-infected individual failed to recognize the Gag 349±359 peptide (Fig. 3c, middle) . The binding af®nity of these peptides to HLA-A Ã 1101 was almost identical (Fig. 3c, lower) , suggesting that the substitution at P9 affects TCR recognition by speci®c CTL but not HLA-A Ã 1101 binding.
Overall, these results for CTL cross-recognition suggest that HIV-1 clade B-and clade E-speci®c sequences corresponding to Pol 675±683, Nef 84±92, and Gag 349±359 are recognized as clade-speci®c epitopes in HIV-1 clade B-infected and HIV-1 clade E-infected individuals, respectively. To determine whether the clade E-speci®c sequences are naturally occurring epitopes, we tested the cytolytic activity of clade Especi®c CTL for target cells infected with HIV-1 recombinant vaccinia virus containing the Nef 84±92-2F6F or Gag 349±359-9S sequence. Bulk CTL cultures speci®c for Nef 84±92-2F6F or Gag 349±359-9S effectively lysed HLA-A Ã 1101 target cells infected with the corresponding HIV-1 recombinant vaccinia virus (Figs 3d and 3e) . These results indicate that these two peptides are naturally occurring epitopes.
CTL epitopes unique to HIV-1 clade B There are three dominant sequences for the Env 202± 210 epitope in HIV-1 clades A±E: Env 202±210 is predominantly observed in clade B, Env 202±210-4K in clade E, and Env 202±210-2A in clades A, C and D (Table 1) . CTL activity for Env 202±210 was induced in PBMC from HIV-1 clade B-infected HLA-A Ã 1101 individuals. However, CTL activity for Env 202±210-4K was not induced in PBMC from HIV-1 clade Einfected individuals (Fig. 1 ). These observations suggest that Env 202±210 is a clade B-speci®c CTL epitope but that Env 202±210-4K does not function as an epitope. Indeed, an Env 202±210-speci®c CTL clone recognized Env 202±210-2A but not Env 202±210-4K (data not shown). Since the binding af®nity of all three peptides to HLA-A Ã 1101 was almost identical (data not shown), it is likely that the substitution of Lys for Thr is critical for TCR recognition by the CTL clone. Another possibility is that Env 202±210-4K is not recognized by these HIV-1 clade E-infected individuals as this is not an immunodominant epitope.
There are four dominant sequences for the Gag 83-90 epitope in HIV-1 clades A±E: Gag 83±90 and Gag 83±90-8K are predominantly found in clade B while Gag 83±90-3W and Gag 83±90-7E are predominantly observed in clades E and D, respectively (Table 1) . CTL activity for Gag 83±90 was not induced in PBMC from ®ve HLA-A Ã 1101 individuals infected with HIV-1 clade B while CTL activity for Gag 83± 90-8K was induced in PBMC from only one of these individuals (Fig. 1) . CTL activity for the clade Especi®c peptide Gag 83±90-3W was not induced in PBMC from any of the HIV-1 clade E-infected individuals (Fig. 1) . These results suggest that Gag 83± 90-8K is a clade B-speci®c epitope but is not dominant, and that Gag 83±90-3W is not a clade E-speci®c epitope or not an immunodominant epitope. CTL induced by Gag 83±90-8K failed to recognize the other three Gag 83±90 variants (data not shown). As these peptides showed similar binding af®nity to HLA-A Ã 1101 (data not shown), it is likely that the substitutions at P3, P7 and P8 are critical for TCR recognition by speci®c CTL.
CTL recognition of target cells infected with HIV-1 clade E
This and previous studies [22, 29] showed that the three cross-clade epitopes and two of the clade E-speci®c epitopes are naturally processed in target cells infected with HIV-1 recombinant vaccinia virus. However, cells infected with HIV-1 recombinant vaccinia virus are not an exact model for individuals infected with HIV-1. It is therefore important to clarify whether T cells speci®c for these epitopes recognize the epitopes when presented by cells infected with HIV-1. We investigated the cytolytic activity of CTL speci®c for the three cross-clade and three clade E-speci®c epitopes for target cells infected with an HIV-1 clade E clone, p93JP-NH1, which has these epitope sequences. We generated a CXCR4 CD4 HLA-A Ã 1101 cell line, 721.221-CD4-A Ã 1101, by transfection of HLA class I À CXCR4 721.221 cells with HLA-A Ã 1101 and CD4 genes. The transfected cells were then infected with the HIV-1 clade E clone. After culture for 6±7 days, the cells were tested for infection by¯ow cytometry every 2 days. When approximately 95% of the cells were stained with anti-p24 mAb, the cells were used as target cells for a CTL assay. Down-regulation of HLA-A Ã 1101 was observed in approximately 30% of the infected cells (Fig. 4a ). An HLA-A Ã 2402-restricted, Gag 263±272-speci®c CTL clone failed to lyse infected target cells (Fig. 4b) . Pol 424±432-speci®c and Pol 894±903-speci®c CTL clones as well as Pol 313±321-speci®c bulk CTL effectively lysed infected target cells but failed to lyse uninfected 721.221-CD4-A Ã 1101 cells (Fig. 4b) . These results indicate that these crossclade epitopes are naturally processed and presented in cells infected with HIV-1 clade E clone 93JP-NH1. Pol 675±683-5E-speci®c CTL clone as well as Nef 84-92-2F6F-speci®c and Gag 349-359-9S-speci®c bulk CTL effectively lysed infected target cells but failed to lyse uninfected 721.221-CD4-A Ã 1101 cells (Fig. 4b) . This indicates that these clade E-speci®c epitopes are also naturally processed and presented in cells infected with the HIV-1 clade E clone p93JP-NH1.
Discussion
We identi®ed six HLA-A Ã 1101-restricted CTL epitopes in individuals infected with HIV-1 clade E; three are cross-clade epitopes between clades B and E and three are clade E-speci®c epitopes. Of the three crossclade epitopes, statistical analysis suggested that Pol 313±321 is an immunodominant epitope in HIV-1 clade E-infected individuals but not in HIV-1 clade Binfected individuals. As a strong speci®c CTL activity for this epitope (relative speci®c lysis, 53.5% and 67.3%) was induced in two out of ®ve clade B-infected individuals, this epitope might be recognized as a subdominant epitope. The sequence of this epitope is [18, 19] . We here identi®ed three cross-clade epitopes between clades B and E. Such epitopes are useful for HIV vaccine design.
Of the three clade E-speci®c epitopes, statistical analysis suggested that Nef 84±92-2F6F is an immunodominant epitope in HIV-1 clade E-infected individuals. On the other hand, Gag 349±359-9S is not indicated as immunodominant epitope by statistical analysis. However, as a strong Gag 349±359-9S-speci®c CTL activity was induced in three out of seven HIV-1 clade E- infected individuals, Gag 349±359-9S may be an subdominant epitope in those infected with HIV-1 clade E. Similarly, Pol 675±683-5E may be subdominant as Pol 675±683-5E-speci®c CTL were induced in three out of seven clade E-infected individuals tested. Further analysis of these epitopes in HIV-1 clade Einfected individuals is expected to characterize them more accurately. This study is the ®rst report of HIV-1 clade E-speci®c CTL epitopes. Furthermore, we showed that the strategy of using known clade B epitopes to identify non-clade B epitopes is very useful. It should be noted, however, that this strategy may not be useful for identifying Env epitopes as Env is more diverse between HIV-1 clades than other HIV-1 proteins. Identi®cation of clade E Env epitopes is now under investigation using reverse immunogenetics, a more effective strategy for identifying such epitopes. The clade E epitopes identi®ed in the present study will contribute to various studies of HIV-1-speci®c CTL in Asian countries.
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